SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-98858"
 

Sökning: id:"swepub:oai:DiVA.org:oru-98858" > A Head-to-head Comp...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005355naa a2200505 4500
001oai:DiVA.org:oru-98858
003SwePub
008220505s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:149515314
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-988582 URI
0247 a https://doi.org/10.1016/j.euros.2022.01.0102 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1495153142 URI
040 a (SwePub)orud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Waldén, Mauritzu Department of Urology, Central Hospital of Karlstad, Karlstad, Sweden4 aut
2451 0a A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines :b Results from a Prospective Population-based Screening Study
264 1b Elsevier,c 2022
338 a print2 rdacarrier
520 a Background: Strategies for early detection of prostate cancer aim to detect clinically significant prostate cancer (csPCa) and avoid detection of insignificant cancers and unnecessary biopsies. Swedish national guidelines (SNGs), years 2019 and 2020, involve prostate-specific antigen (PSA) testing, clinical variables, and magnetic resonance imaging (MRI). The Stockholm3 test and MRI have been suggested to improve selection of men for prostate biopsy. Performance of SNGs compared with the Stockholm3 test or MRI in a screening setting is unclear.Objective: To compare strategies based on previous and current national guidelines, Stockholm3, and MRI to select patients for biopsy in a screening-by-invitation setting.Design setting and participants: All participants underwent PSA test, and men with PSA ≥3 ng/ml underwent Stockholm3 testing and MRI. Men with Stockholm3 ≥11%, Prostate Imaging Reporting and Data System score ≥3 on MRI, or indication according to SNG-2019 or SNG-2020 were referred to biopsy.Outcome measurements and statistical analysis: The primary outcome was the detection of csPCa at prostate biopsy, defined as an International Society of Urological Pathology (ISUP) grade of ≥2.Results and limitations: We invited 8764 men from the general population, 272 of whom had PSA ≥3 ng/ml. The median PSA was 4.1 (interquartile range: 3.4-5.8), and 136 of 270 (50%) who underwent MRI lacked any pathological lesions. In total, 37 csPCa cases were diagnosed. Using SNG-2019, 36 csPCa cases with a high biopsy rate (179 of 272) were detected and 49 were diagnosed with ISUP 1 cancers. The Stockholm3 strategy diagnosed 32 csPCa cases, with 89 biopsied and 27 ISUP 1 cancers. SNG-2020 detected 32 csPCa and 33 ISUP 1 cancer patients, with 99 men biopsied, and the MRI strategy detected 30 csPCa and 35 ISUP 1 cancer cases by biopsying 123 men. The latter two strategies generated more MRI scans than the Stockholm3 strategy (n = 270 vs 33).Conclusions: Previous guidelines provide high detection of significant cancer but at high biopsy rates and detection of insignificant cancer. The Stockholm3 test may improve diagnostic precision compared with the current guidelines or using only MRI.Patient summary: The Stockholm3 test facilitates detection of significant cancer, and reduces the number of biopsies and detection of insignificant cancer.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Cancer screening
653 a Magnetic resonance imaging
653 a Prostate cancer
653 a Prostate cancer screening
653 a Prostate neoplasm
653 a Stockholm3
7001 a Aldrimer, Mattiasu Department of Clinical Chemistry, Central Hospital of Karlstad, Karlstad, Sweden4 aut
7001 a Heydorn Lagerlöf, Jakob,d 1978-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Medical Physics, Central Hospital of Karlstad, Karlstad, Sweden; Department of Medical Physics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden4 aut0 (Swepub:oru)jhf
7001 a Eklund, Martinu Karolinska Institutet4 aut
7001 a Grönberg, Henriku Karolinska Institutet4 aut
7001 a Nordström, Tobiasu Karolinska Institutet4 aut
7001 a Palsdottir, Thorgerduru Karolinska Institutet4 aut
7102 a Department of Urology, Central Hospital of Karlstad, Karlstad, Swedenb Department of Clinical Chemistry, Central Hospital of Karlstad, Karlstad, Sweden4 org
7730 t European Urology Open Scienced : Elsevierg 38, s. 32-39q 38<32-39x 2666-1691x 2666-1683
8564 u https://doi.org/10.1016/j.euros.2022.01.010y Fulltext
8564 u https://doi.org/10.1016/j.euros.2022.01.010
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-98858
8564 8u https://doi.org/10.1016/j.euros.2022.01.010
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:149515314

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy